Last reviewed · How we verify

nortriptyline + topiramate

University of California, Irvine · FDA-approved active Small molecule

This combination uses nortriptyline (a tricyclic antidepressant that inhibits norepinephrine and serotonin reuptake) together with topiramate (an anticonvulsant with multiple mechanisms including sodium channel blockade and carbonic anhydrase inhibition) to treat pain and mood disorders.

This combination uses nortriptyline (a tricyclic antidepressant that inhibits norepinephrine and serotonin reuptake) together with topiramate (an anticonvulsant with multiple mechanisms including sodium channel blockade and carbonic anhydrase inhibition) to treat pain and mood disorders. Used for Chronic pain conditions, Depression with comorbid pain, Migraine prophylaxis.

At a glance

Generic namenortriptyline + topiramate
Also known asPamelor, Topamax
SponsorUniversity of California, Irvine
Drug classTricyclic antidepressant + anticonvulsant combination
TargetNorepinephrine transporter, serotonin transporter, voltage-gated sodium channels, GABA receptors
ModalitySmall molecule
Therapeutic areaPsychiatry, Neurology, Pain Management
PhaseFDA-approved

Mechanism of action

Nortriptyline enhances monoaminergic neurotransmission by blocking reuptake of norepinephrine and serotonin, which modulates pain perception and mood. Topiramate acts through multiple mechanisms including voltage-gated sodium channel blockade, potentiation of GABA, and carbonic anhydrase inhibition, contributing to analgesic and mood-stabilizing effects. The combination leverages complementary mechanisms for enhanced efficacy in conditions like chronic pain and depression.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results